Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
corticosteroid-induced osteoporosis (622) 622
humans (453) 453
osteoporosis (299) 299
female (290) 290
male (240) 240
bone-mineral density (218) 218
osteoporosis - chemically induced (217) 217
glucocorticoids - adverse effects (208) 208
endocrinology & metabolism (200) 200
glucocorticoid-induced osteoporosis (189) 189
middle aged (183) 183
rheumatology (179) 179
prevention (175) 175
bone density - drug effects (158) 158
index medicus (151) 151
rheumatoid-arthritis (146) 146
aged (139) 139
double-blind (138) 138
osteoporosis - drug therapy (137) 137
osteoporosis - prevention & control (134) 134
adult (132) 132
bone density (126) 126
glucocorticoids (122) 122
postmenopausal women (122) 122
corticosteroids (116) 116
risk factors (113) 113
therapy (113) 113
alendronate (102) 102
fractures (100) 100
diphosphonates - therapeutic use (97) 97
bone density conservation agents - therapeutic use (96) 96
medicine, general & internal (91) 91
animals (89) 89
mineral density (85) 85
bone mineral density (83) 83
calcium (81) 81
bisphosphonates (80) 80
vertebral fracture (80) 80
postmenopausal osteoporosis (77) 77
steroid-induced osteoporosis (72) 72
vitamin d (72) 72
oral corticosteroids (70) 70
orthopedics (67) 67
medicine & public health (64) 64
vitamin-d (62) 62
glucocorticoids - therapeutic use (61) 61
absorptiometry, photon (60) 60
risedronate (60) 60
management (59) 59
steroids (59) 59
hormone replacement therapy (57) 57
parathyroid-hormone (57) 57
vertebral fractures (57) 57
induced bone loss (55) 55
osteoporosis - physiopathology (55) 55
alfacalcidol (53) 53
glucocorticoid (52) 52
women (52) 52
bones (51) 51
pharmacology & pharmacy (51) 51
drug therapy (50) 50
osteoporosis - etiology (50) 50
osteoporosis - therapy (50) 50
adolescent (49) 49
fracture (49) 49
vitamin d - therapeutic use (49) 49
osteoporosis - diagnosis (48) 48
care and treatment (47) 47
fractures, bone - prevention & control (47) 47
bone (46) 46
treatment outcome (45) 45
intermittent cyclical etidronate (44) 44
risk (44) 44
bone and bones - drug effects (43) 43
bone loss (42) 42
osteoporosis - complications (42) 42
cyclical etidronate (41) 41
density (41) 41
glucocorticoids - administration & dosage (41) 41
salmon-calcitonin (41) 41
aged, 80 and over (40) 40
etidronic acid - therapeutic use (39) 39
randomized controlled-trial (39) 39
bone and bones - metabolism (38) 38
bone density - physiology (38) 38
alendronate - therapeutic use (37) 37
endocrinology (37) 37
induced osteopenia (37) 37
complications and side effects (36) 36
fractures, bone - etiology (36) 36
osteoporosis - epidemiology (36) 36
placebo-controlled trial (36) 36
calcitonin (35) 35
calcium - therapeutic use (35) 35
adrenal cortex hormones - adverse effects (34) 34
drug therapy, combination (33) 33
osteoporosis, postmenopausal - drug therapy (33) 33
double-blind method (32) 32
rats (32) 32
prospective studies (31) 31
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (636) 636
German (24) 24
French (11) 11
Spanish (5) 5
Polish (2) 2
Russian (2) 2
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Osteoporosis
by Simon, LS
RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, ISSN 0889-857X, 02/2007, Volume 33, Issue 1, pp. 149 - 149
Effective therapies are available for the patient who has arthritic osteoporosis. The approach is critical to ensure an optimal quality of life in these... 
ESTROGEN REPLACEMENT THERAPY | TUMOR-NECROSIS-FACTOR | POSTMENOPAUSAL BONE LOSS | POST-MENOPAUSAL OSTEOPOROSIS | GLUCOCORTICOID-INDUCED OSTEOPOROSIS | INTESTINAL CALCIUM-ABSORPTION | OSTEOBLAST-LIKE CELLS | RHEUMATOLOGY | CORTICOSTEROID-INDUCED OSTEOPOROSIS | DUAL-PHOTON-ABSORPTIOMETRY | INTRANASAL SALMON-CALCITONIN
Journal Article
Details down arrow
2. Full Text Bisphosphonates for steroid-induced osteoporosis
by Allen, Claire S and Yeung, James Hs and Vandermeer, Ben and Homik, Joanne
Cochrane Database of Systematic Reviews, ISSN 1469-493X, 10/2016, Volume 2016, Issue 10, p. CD001347
Background This is an update of a Cochrane Review first published in 1999. Corticosteroids are widely used in inflammatory conditions as an immunosuppressive... 
Glucocorticoids [adverse effects] | Osteoporosis [chemically induced; prevention & control] | Diphosphonates [therapeutic use] | Humans | GLUCOCORTICOID-INDUCED OSTEOPOROSIS | INFLAMMATORY RHEUMATIC-DISEASES | CONNECTIVE-TISSUE DISEASE | INTRAVENOUS PAMIDRONATE | CORTICOSTEROID-INDUCED OSTEOPOROSIS | MEDICINE, GENERAL & INTERNAL | MINERAL DENSITY | VERTEBRAL FRACTURES | DOUBLE-BLIND | INTERMITTENT CYCLICAL ETIDRONATE | INDUCED BONE LOSS | Spinal Fractures - prevention & control | Osteoporosis - chemically induced | Osteoporosis - prevention & control | Bone Density Conservation Agents - therapeutic use | Diphosphonates - therapeutic use | Adult | Glucocorticoids - adverse effects | Randomized Controlled Trials as Topic
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text The prevalence of osteoporosis in patients with chronic obstructive pulmonary disease—A cross sectional study
by Jørgensen, N.R and Schwarz, P and Holme, I and Henriksen, B.M and Petersen, L.J and Backer, V
Respiratory Medicine, ISSN 0954-6111, 2006, Volume 101, Issue 1, pp. 177 - 185
Summary Chronic obstructive pulmonary disease (COPD) is a complex disease, where the initial symptoms are often cough as a result of excessive mucus production... 
Pulmonary/Respiratory | Vertebral fractures | Pulmonary function | Secondary osteoporosis | Corticosteroid induced osteoporosis | COPD | BONE-DENSITY | CARDIAC & CARDIOVASCULAR SYSTEMS | pulmonary function | GLUCOCORTICOID-INDUCED OSTEOPOROSIS | LUNG-FUNCTION | RISK | corticosteroid induced osteoporosis | vertebral fractures | BECLOMETHASONE DIPROPIONATE | secondary osteoporosis | RESPIRATORY SYSTEM | CORTICOSTEROID USE | INHALED STEROIDS | MEN | BODY-MASS | ASTHMA | Spirometry | Bone Density | Prevalence | Cross-Sectional Studies | Humans | Middle Aged | Male | Pulmonary Disease, Chronic Obstructive - physiopathology | Pulmonary Disease, Chronic Obstructive - complications | Bone Diseases, Metabolic - complications | Osteoporosis - complications | Fractures, Bone - complications | Fractures, Bone - physiopathology | Female | Aged | Bone Diseases, Metabolic - physiopathology | Osteoporosis - physiopathology | Osteoporosis | Medical research | Care and treatment | Lung diseases, Obstructive | Medicine, Experimental | Development and progression | Prevalence studies (Epidemiology) | Bones | Bone density | Disease | Older people
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Glucocorticoid-Induced osteoporosis
by Frenkel, Baruch and White, Wendy and Tuckermann, Jan
Advances in Experimental Medicine and Biology, ISSN 0065-2598, 2015, Volume 872, pp. 179 - 215
Osteoporosis is among the most devastating side effects of glucocorticoid (GC) therapy for the management of inflammatory and auto-immune diseases. Evidence... 
FoxO | MKP-1 | Notch | Osteoblast | Akt | Proliferation | GIO | Wnt | RUNX2 | ERK | MEDICINE, RESEARCH & EXPERIMENTAL | EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS | ACTIVATED PROTEIN-KINASE | BONE-MINERAL DENSITY | PROMOTES ADIPOCYTE DIFFERENTIATION | FACTOR-BINDING PROTEIN-5 | HEPATOCYTE GROWTH-FACTOR | CORTICOSTEROID-INDUCED OSTEOPOROSIS | MESENCHYMAL STEM-CELLS | ALKALINE-PHOSPHATASE ACTIVITY | BIOLOGY | SIGNAL-REGULATED KINASE | Protein Kinases - metabolism | Transcription Factors - metabolism | Animals | Bone Density | Osteoporosis - chemically induced | Cell Cycle | Humans | Cell Differentiation | Mice | Osteoblasts - cytology | Glucocorticoids - adverse effects | Apoptosis
Journal Article
Details down arrow
5. Secondary osteoporosis: Pathophysiology and management
by Mirza, Faryal and Canalis, Ernesto
European Journal of Endocrinology, ISSN 0804-4643, 09/2015, Volume 173, Issue 3, pp. R131 - R151
Osteoporosis is a skeletal disorder characterized by decreased mass and compromised bone strength predisposing to an increased risk of fractures. Although... 
ANDROGEN-DEPRIVATION THERAPY | THYROTROPIN-SUPPRESSIVE THERAPY | SYSTEMIC-LUPUS-ERYTHEMATOSUS | INFLAMMATORY-BOWEL-DISEASE | BONE-MINERAL DENSITY | PRIMARY BILIARY-CIRRHOSIS | ENDOCRINOLOGY & METABOLISM | GLUCOCORTICOID-INDUCED OSTEOPOROSIS | RANDOMIZED CONTROLLED-TRIAL | CORTICOSTEROID-INDUCED OSTEOPOROSIS | KAPPA-B LIGAND
Journal Article
Details down arrow
6. Glucocorticoid-induced Osteoporosis
by Whittier, Xena and Saag, Kenneth G
Rheumatic Disease Clinics of North America, ISSN 0889-857X, 2016, Volume 42, Issue 1, pp. 177 - 189
Glucocorticoid-induced osteoporosis (GIOP) is one of the most common and serious adverse effects associated with glucocorticoid use. This article highlights... 
Prevention | Osteoporosis | Glucocorticoids | Fracture risk | BONE-MINERAL DENSITY | ACTIVE RHEUMATOID-ARTHRITIS | LOW-DOSE CORTICOSTEROIDS | VERTEBRAL FRACTURE | RANDOMIZED CONTROLLED-TRIAL | RHEUMATOLOGY | CORTICOSTEROID-INDUCED OSTEOPOROSIS | CONTROLLED CLINICAL-TRIAL | DOUBLE-BLIND | PLACEBO-CONTROLLED TRIAL | POSTMENOPAUSAL WOMEN | Bone Density | Osteoporosis - chemically induced | Osteoporotic Fractures - chemically induced | Osteoporosis - prevention & control | Risk Assessment | Humans | Osteoporotic Fractures - prevention & control | Bone Density Conservation Agents - therapeutic use | Osteoporosis - drug therapy | Glucocorticoids - adverse effects
Journal Article
Details down arrow
7. Osteoporosis
by Simon, LS
CLINICS IN GERIATRIC MEDICINE, ISSN 0749-0690, 08/2005, Volume 21, Issue 3, pp. 603 - 603
Bone is a complex organ which contains an organic matrix which serves as scaffolding, includes mineral as calcium distributed in a pattern providing structure... 
ESTROGEN REPLACEMENT THERAPY | TUMOR-NECROSIS-FACTOR | POSTMENOPAUSAL BONE LOSS | POST-MENOPAUSAL OSTEOPOROSIS | GLUCOCORTICOID-INDUCED OSTEOPOROSIS | INTESTINAL CALCIUM-ABSORPTION | OSTEOBLAST-LIKE CELLS | CORTICOSTEROID-INDUCED OSTEOPOROSIS | DUAL-PHOTON-ABSORPTIOMETRY | INTRANASAL SALMON-CALCITONIN | GERIATRICS & GERONTOLOGY
Journal Article
Details down arrow
8. Full Text Teriparatide or Alendronate in Glucocorticoid-Induced Osteoporosis
by Saag, Kenneth G and Shane, Elizabeth and Boonen, Steven and Marín, Fernando and Donley, David W and Taylor, Kathleen A and Dalsky, Gail P and Marcus, Robert
The New England Journal of Medicine, ISSN 0028-4793, 11/2007, Volume 357, Issue 20, pp. 2028 - 2039
This study compared teriparatide, an anabolic agent, with alendronate in an 18-month randomized, double-blind, controlled trial involving patients who had... 
MEDICINE, GENERAL & INTERNAL | MANAGEMENT | BONE-MINERAL DENSITY | VERTEBRAL FRACTURE RISK | DOUBLE-BLIND | PREVENTION | PARATHYROID-HORMONE | RANDOMIZED-TRIAL | RISEDRONATE | CORTICOSTEROID-INDUCED OSTEOPOROSIS | POSTMENOPAUSAL WOMEN | Teriparatide - therapeutic use | Humans | Middle Aged | Fractures, Bone - epidemiology | Male | Osteoporosis - drug therapy | Risk | Bone Remodeling - drug effects | Alendronate - therapeutic use | Calcium - blood | Aged, 80 and over | Female | Glucocorticoids - adverse effects | Lumbar Vertebrae - physiology | Osteoporosis - chemically induced | Teriparatide - pharmacology | Bone Density Conservation Agents - adverse effects | Double-Blind Method | Bone Density Conservation Agents - therapeutic use | Lumbar Vertebrae - drug effects | Biomarkers - blood | Bone Density Conservation Agents - pharmacology | Alendronate - adverse effects | Bone Density - drug effects | Alendronate - pharmacology | Teriparatide - adverse effects | Aged | Fractures, Bone - prevention & control | Osteoporosis | Complications and side effects | Corticosteroids | Alendronate | Bones | Dosage and administration | Research | Drug therapy | Comparative analysis | Health aspects | Density | Risk factors | Women | Bone density | Older people
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Glucocorticoid-induced osteoporosis: pathophysiology and therapy
by Canalis, E and Mazziotti, G and Giustina, A and Bilezikian, J P
Osteoporosis International, ISSN 0937-941X, 10/2007, Volume 18, Issue 10, pp. 1319 - 1328
Glucocorticoid-induced osteoporosis (GIO) is the most common form of secondary osteoporosis. Fractures, which are often asymptomatic, may occur in as many as... 
Glucocorticoid-induced osteoporosis | Fractures | Medicine & Public Health | Gynecology | Orthopedics | Rheumatology | Bone mineral density | Endocrinology | BONE-MINERAL DENSITY | 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE-1 | OSTEOBLAST-LIKE CELLS | CORTICOSTEROID-INDUCED OSTEOPOROSIS | ALKALINE-PHOSPHATASE ACTIVITY | bone mineral density | CULTURED RAT CALVARIAE | BINDING-PROTEIN EXPRESSION | ENDOCRINOLOGY & METABOLISM | glucocorticoid-induced osteoporosis | PARATHYROID-HORMONE | RADIOLOGICAL SPINAL DEFORMITIES | fractures | GH-RELEASING HORMONE | Osteocytes - drug effects | Bone Density | Osteoporosis - chemically induced | Osteoporosis - therapy | Humans | Osteoblasts - drug effects | Male | Treatment Outcome | Guideline Adherence | Fractures, Bone - physiopathology | Female | Vitamin D - therapeutic use | Fractures, Bone - chemically induced | Fractures, Bone - therapy | Glucocorticoids - adverse effects | Osteoporosis | Bone density | Steroids
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Management of glucocorticoid-induced osteoporosis
by Compston, Juliet
Nature Reviews Rheumatology, ISSN 1759-4790, 02/2010, Volume 6, Issue 2, pp. 82 - 88
Glucocorticoid-induced osteoporosis is a common condition that results in significant morbidity and mortality. The skeletal effects of glucocorticoids include... 
CONTROLLED CLINICAL-TRIAL | BONE-MINERAL DENSITY | VERTEBRAL FRACTURE RISK | INTERMITTENT PARATHYROID-HORMONE | DOUBLE-BLIND | INHALED CORTICOSTEROIDS | PREVENTION | RHEUMATOLOGY | CORTICOSTEROID-INDUCED OSTEOPOROSIS | POSTMENOPAUSAL WOMEN | PRACTICE PATTERNS | Osteoporosis - chemically induced | Humans | Bone Density Conservation Agents - therapeutic use | Osteoporosis - drug therapy | Osteoporosis - physiopathology | Glucocorticoids - adverse effects | Practice Guidelines as Topic | Complications and side effects | Osteoporosis | Corticosteroids | Diphosphonates | Dosage and administration | Research | Drug therapy | Risk factors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Glucocorticoid-induced osteoporosis: an update
by Compston, Juliet
Endocrine, ISSN 1355-008X, 7/2018, Volume 61, Issue 1, pp. 7 - 16
Glucocorticoid-induced osteoporosis is the most common secondary cause of osteoporosis and the resulting fractures cause significant morbidity. Following... 
Medicine & Public Health | Glucocorticoids | Science, Humanities and Social Sciences, multidisciplinary | Internal Medicine | Bone density | Fracture | Diabetes | Bisphosphonates | Endocrinology | Teriparatide | BONE-MINERAL DENSITY | INHALED CORTICOSTEROIDS | VERTEBRAL FRACTURE | CORTICOSTEROID-INDUCED OSTEOPOROSIS | FRACTURE RISK | ALENDRONATE | ORAL CORTICOSTEROIDS | ENDOCRINOLOGY & METABOLISM | DOUBLE-BLIND | RISEDRONATE | POSTMENOPAUSAL WOMEN | Guidelines as Topic | Osteoporosis - chemically induced | Osteoporosis - therapy | Humans | Osteoporosis - complications | Bone Density Conservation Agents - therapeutic use | Fractures, Bone - epidemiology | Glucocorticoids - adverse effects | Bone and Bones - drug effects | Osteoporosis - epidemiology | Calcifediol | Corticosteroids | Research | Alfacalcidol | Vitamin D | Phosphonates | Review
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Comparative effects of teriparatide and risedronate in glucocorticoid‐induced osteoporosis in men: 18‐month results of the EuroGIOPs trial
by Glüer, Claus‐C and Marin, Fernando and Ringe, Johann D and Hawkins, Federico and Möricke, Rüdiger and Papaioannu, Nikolaos and Farahmand, Parvis and Minisola, Salvatore and Martínez, Guillermo and Nolla, Joan M and Niedhart, Christopher and Guañabens, Nuria and Nuti, Ranuccio and Martín‐Mola, Emilio and Thomasius, Friederike and Kapetanos, Georgios and Peña, Jaime and Graeff, Christian and Petto, Helmut and Sanz, Beatriz and Reisinger, Andreas and Zysset, Philippe K
Journal of Bone and Mineral Research, ISSN 0884-0431, 06/2013, Volume 28, Issue 6, pp. 1355 - 1368
ABSTRACT Data on treatment of glucocorticoid‐induced osteoporosis (GIO) in men are scarce. We performed a randomized, open‐label trial in men who have taken... 
GLUCOCORTICOID‐INDUCED OSTEOPOROSIS | BONE MINERAL DENSITY | BONE MICROSTRUCTURE | VERTEBRAL FRACTURE | FINITE ELEMENT ANALYSIS | MALE OSTEOPOROSIS | HIGH RESOLUTION QUANTITATIVE COMPUTED TOMOGRAPHY | GLUCOCORTICOID-INDUCED OSTEOPOROSIS | QUANTITATIVE COMPUTED-TOMOGRAPHY | CORTICOSTEROID-INDUCED OSTEOPOROSIS | FRACTURE RISK | ALENDRONATE | TRABECULAR BONE | THERAPY | ENDOCRINOLOGY & METABOLISM | PARATHYROID-HORMONE | POSTMENOPAUSAL WOMEN | VERTEBRAL MICROSTRUCTURE | FINITE-ELEMENT-ANALYSIS | Glucocorticoids - administration & dosage | Follow-Up Studies | Humans | Middle Aged | Osteoporosis - drug therapy | Spinal Fractures - metabolism | Osteoporosis - metabolism | Osteoporosis - diagnostic imaging | Aged, 80 and over | Adult | Female | Risedronate Sodium | Etidronic Acid - analogs & derivatives | Glucocorticoids - adverse effects | Etidronic Acid - administration & dosage | Lumbar Vertebrae - metabolism | Osteoporosis - chemically induced | Bone Density Conservation Agents - adverse effects | Lumbar Vertebrae - diagnostic imaging | Teriparatide - administration & dosage | Europe | Bone Density Conservation Agents - administration & dosage | Spinal Fractures - diagnostic imaging | Radiography | Bone Density - drug effects | Aged | Osteoporosis | Corticosteroids | Comparative analysis | Steroids | Tomography | Bone density | Original
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Management of Glucocorticoid-Induced Osteoporosis
by Rizzoli, R and Adachi, J D and Cooper, C and Dere, W and Devogelaer, J P and Diez-Perez, A and Kanis, J A and Laslop, A and Mitlak, B and Papapoulos, S and Ralston, S and Reiter, S and Werhya, G and Reginster, J Y
Calcified Tissue International, ISSN 0171-967X, 10/2012, Volume 91, Issue 4, pp. 225 - 243
This review summarizes the available evidence-based data that form the basis for therapeutic intervention and covers the current status of... 
Life Sciences | Biochemistry, general | Osteoporosis | FRAX | Bone therapy | Orthopedics | Fracture | Glucocorticoid | Endocrinology | Cell Biology | LONG-TERM | BONE-MINERAL DENSITY | INHALED CORTICOSTEROIDS | CORTICOSTEROID-INDUCED OSTEOPOROSIS | METHYLPREDNISOLONE PULSE THERAPY | VERTEBRAL FRACTURE RISK | ORAL CORTICOSTEROIDS | ENDOCRINOLOGY & METABOLISM | DOUBLE-BLIND | LOW-DOSE PREDNISONE | POSTMENOPAUSAL WOMEN | Osteoporosis - chemically induced | Humans | Calcium - administration & dosage | Bone Density Conservation Agents - therapeutic use | Osteoporosis - drug therapy | Clinical Trials as Topic | Bone Density - drug effects | Diphosphonates - therapeutic use | Vitamin D - administration & dosage | Disease Management | Fractures, Bone - chemically induced | Dietary Supplements | Fractures, Bone - prevention & control | Glucocorticoids - adverse effects | Osteoporosis - epidemiology | Bone density | Fractures | Drug therapy | Steroids | Economics | Calcium | Glucocorticoids | Therapeutic applications | Clinical trials | Bisphosphonates | Post-menopause | Algorithms | Reviews | Vitamin D | Parathyroid hormone | Risk assessment | Bone mineral density | Bone | Supplementation | Osteoarthritis | Geriatrics
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights